Sort   by:  
 Page size 
UnknownStomach cancer risk after treatment for hodgkin lymphoma.
Not available
S-EPMC3770865 | biostudies-literature
UnknownIndividual differences in prospective and retrospective memory offloading.
Not available
S-EPMC12263121 | biostudies-literature
UnknownCytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study.
Not available
S-EPMC12486802 | biostudies-literature
UnknownZanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Not available
S-EPMC9300083 | biostudies-literature
UnknownZanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up.
Not available
S-EPMC7596846 | biostudies-literature
UnknownThe Concept of Scaffold-Guided Bone Regeneration for the Treatment of Long Bone Defects: Current Clinical Application and Future Perspective.
Not available
S-EPMC10381286 | biostudies-literature
UnknownPhase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Not available
S-EPMC6742923 | biostudies-literature
UnknownInternational consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set.
Not available
S-EPMC11667046 | biostudies-literature
UnknownPooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
Not available
S-EPMC8864647 | biostudies-literature
UnknownAdvancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable.
Not available
S-EPMC11462221 | biostudies-literature
Sort   by:  
 Page size